Physician profile
James Muns
NPI 1164471389
$9,539.86
in general payments reported to CMS, 2019-2025
58 companies · $1,955 in 2025
The $1,955 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,944 · 2020: $232 · 2021: $697 · 2022: $1,149 · 2023: $1,667 · 2024: $1,896 · 2025: $1,955.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,518.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,517.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,004.04 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $944.85 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $872.62 | 2019-2025 | Evenity, Repatha, Otezla |
| Glaxosmithkline, LLC. | $776.01 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbott Laboratories | $629.46 | 2021-2025 | Freestyle Libre 3, Eterna |
| Abbvie INC. | $564.26 | 2019-2025 | |
| Pfizer INC. | $562.82 | 2019-2025 | |
| Lilly USA, LLC | $551.38 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $337.85 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $320.45 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Astellas Pharma US INC | $296.01 | 2019-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $261.49 | 2019-2025 | Xifaxan |
| Amarin Pharma, INC. | $200.00 | 2019-2022 | |
| Corcept Therapeutics | $168.29 | 2024-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $168.11 | 2019-2025 | Jardiance |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Muns listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.